The Upjohn Company has recently released a new glyburide tablet that is designed to improve absorption and dosing flexibility for people with Type 2 diabetes.
The Glynase PresTab tablet is a patented 3 mg glyburide tablet that divides easily in two with the press of a finger. This new design allows diabetes patients to measure their prescribed daily dosage easily and accurately, with a consistent available potency between 90% and 100%.
According to the Upjohn Company, Glynase PresTab’s improved potency allows patients to take a dosage lower than the already available Micronase glyburide tablet and still expect the same results. The Upjohn Company recommends that patients have their dosage readjusted by a doctor before switching from Micronase or other hypoglycemic agents to Glynase PresTab.